Clinical Trial Update: Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparing pembrolizumab to docetaxel in previously treated non-small cell lung cancer has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: COMPLETED | Results posted: 2020-10-05